Pipeline — Biologic Therapeutic Candidates
台康生技開發高質量的生物產品，推進廣泛的候選產品線，以改善患者的生活。
| 產品 | 藥物類別 | 適應症 | 標靶/靶點 | 研發進度 | 合作夥伴 | |||
|---|---|---|---|---|---|---|---|---|
| 臨床前試驗 | 臨床一期 | 臨床二/三期 | 上市許可申請 | |||||
EG12014* (EIRGASUN® / HERWENDA®) Trastuzumab biosimilar | Monoclonal Antibody | HER2+ Breast Cancer (BC) | HER 2 |  |  | |||
EG1206A Pertuzumab biosimilar | Monoclonal Antibody | HER2+ BC | HER 2 | | | |||
EG12043 (TSY110) Kadcyla biosimilar | Antibody Drug Conjugate (ADC) | HER2+ BC | HER 2 | |  | |||
EG13084 Phesgo (SC formulation) | Monoclonal Antibody | HER2+ BC | HER 2 | | - | |||
EG12112 Atezolizumab biosimilar | Monoclonal Antibody | Solid Tumors | PD-L1 | | - | |||
EG12164 Daratumumab biosimilar | Monoclonal Antibody | Myeloma | CD38 | | - | |||
EG7412F Hyaluronidase (rHuPH20) | Enzyme | N/A | High-dose mAb forms. | | - | |||
EG12170 Trastuzumab-deruxtecan biosimilar | Antibody Drug Conjugate | HER2+ BC | HER 2 | | | |||
